Shenzhen in Vivo Biomedicine Technology Limited Company

Guangdong Zhaotai Invivo Biomedicine Co., Ltd

Simiao Lin

Peng Li

Yao Yao

Zhaoyang Tang

Yuanbin Cui

Yunxin Lai

Ruocong Zhao

Le Qin

The present disclosure relates to a scFv amino acid sequence capable of recognizing CD19 antigen and a nucleotide sequence encoding the same, and also relates to a chimeric antigen receptor, a nucleic acid encoding the same and a cell expressing the same, and their uses in the manufacture of a medicament for treating tumors. The chimeric antigen receptor of the present disclosure comprises at least one extracellular domain, an optional transmembrane domain and at least one intracellular costimulatory signaling domain, wherein the extracellular domain comprises a CD19 antigen-recognizing and binding domain. The chimeric antigen receptor of the present disclosure has been humanized, resulting in a longer survival period in vivo, and a corresponding extended complete remission period in patients.

ScFv amino acid sequence, chimeric antigen receptor containing same and application thereof

The present invention relates to a chimeric antigen receptor, a nucleic acid encoding the same and a cell expressing the same, and their use in manufacturing drugs for treating tumors. The chimeric antigen receptor of the present invention is characterized by its intracellular domain including at least Toll-like receptor 1 and/or Toll-like receptor 2 intracellular domain(s); compared to the prior art, the chimeric antigen receptors of the present invention has significant advantages in T cell expansion, cytotoxicity, T cell invasion and migration, eliminating immunosuppressive effect of regulatory T cells and promoting the formation of memory T cells, etc.

Chimeric antigen receptor containing a toll-like receptor intracellular domain

Growing community of inventors

Shenzhen, China

Simiao Lin